More on KPTI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.40 |
|
|||
| Open | $9.60 | ||||
| 52 Wk High | $19.41 | ||||
| 52 Wk Low | $4.83 | ||||
| Day High | $9.74 | ||||
| Day Low | $8.90 | ||||
| P/E | N/A | ||||
| EPS | $-2.74 | ||||
| Volume | 492,124 | ||||
- H.C. Wainwright Reiterates Buy Rating on Karyopharm Therapeutics (KPTI)
- Karyopharm Therapeutics (KPTI) Reiterated at Overweight by Cantor Fitzgerald
- Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: T. Rowe Price Investment Management, Inc.
- Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
- Karyopharm cancer trial selected for late-breaking presentation at EHA
- Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
- Karyopharm presents phase 3 trial results at ASCO 2026
- Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of C
- Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm schedules investor call on myelofibrosis trial results
Entities mentioned with KPTI
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
